Gender difference meta-analyses should be used more in NDAs, FDAer recommends.
Executive Summary
GENDER DIFFERENCE META-ANALYSES IN NDAs RECOMMENDED BY FDAer Stella Machado, PhD, Quantitative Methods & Research Staff director, during the agency's "Gender Studies in Product Development Workshop" Nov. 7. Machado suggested "more use of meta-analysis to maximize the information gained on drug effects on both genders." However, she reminded the audience, "this whole area of meta-analysis requires creativity and thought."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: